Replies to post #72087 on Biotech Values

[ghmm]

UTHR:

Don't know if you noticed in the updated calendar but UTHR decided to amend the FREEDOM-M study so I guess we'll never know at my theory it had a better then average chance to show success (unless of course if fails :-)). A smart move IMO since the dose ranging study wouldn't be done for some time anyway and they likely would have need < .01 to get approval on just the M data. They are proposing to add 100 patients starting at the low dose titration (.25mg). Slides are available from JPM were they mention that at http://ir.unither.com/events.cfm

Do you (or anyone else) have a good link or data on the various efficacy rate of the Interferon's in MS (and Tysabri). Or is it better to not be lazy and just read the labels :-). TIA

[DewDiligence]

Re: Cladribine for MS

Teva as always doesn't say much and I think that royalties were not disclosed by Merck/Serono or Ivax either. But analysts were talking a mid-teens (15% max) royalty on sales to Ivax.

Compared to the industry standard, 15% seems a little high for the kind of formulation work Ivax did; most such royalties are less than 10%.

In any case, if the analysts’ sales projections for Cladribine are even in the ballpark, these royalties have the potential to be material even for a company as large as Teva.